Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database

Abstract

Rimple Jeet Kaur,1 Siddhartha Dutta,1 Jaykaran Charan,1 Pankaj Bhardwaj,2 Ankita Tandon,3 Dharamveer Yadav,4 Salequl Islam,5 Mainul Haque6 1Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; 2Department of Community and Family Medicine, All India Institute of Medical Sciences (AIIMS), Jodhpur, Rajasthan, India; 3Department of Oral Pathology, Microbiology and Forensic Odontology, Dental Institute, Rajendra Institute of Medical Sciences, Ranchi, 834009, India; 4Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; 5Department of Microbiology, Jahangirnagar University, Savar, Dhaka, 1342, Bangladesh; 6Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, 57000, Kuala Lumpur, MalaysiaCorrespondence: Jaykaran CharanDepartment of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, IndiaEmail [email protected] HaqueUnit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sungai Besi, 57000, Kuala Lumpur, MalaysiaEmail [email protected]: Thirteen COVID-19 vaccines are granted emergency approval. It is crucial to monitor their adverse events post vaccination. The present study focuses on cardiovascular adverse events post-COVID-19 vaccination and aims to determine adverse events with the administered vaccine.Methodology: The cardiovascular (CVS) adverse events were extracted for three broad headings (SOCs) – cardiac disorders, vascular disorders, and investigations. Descriptive statistics were reported in the form of percentage and frequency, and the disproportionality analysis was conducted.Results: For the cardiovascular system, 4863 adverse events (AEs) were reported from BNT162b2 Pfizer, 1222 AstraZeneca, Moderna, and other COVID-19 vaccines. Common adverse events observed with vaccines under study were tachycardia (16.41%), flushing (12.17%), hypertension (5.82%), hypotension (3.60%) and peripheral coldness (2.41%). Based on disproportionality analysis (IC025 values), acute myocardial infarction, cardiac arrest, and circulatory collapse were linked to the vaccines in the age group > 75 years. Hypertension, severe hypertension, supraventricular tachycardia, sinus tachycardia, and palpitations were associated across all age groups and either gender. Amongst the investigations, abnormal ECG findings raised C-reactive protein, elevated D dimer, and troponin were reported in specific age groups or gender or all subjects.Conclusion: Although cardiovascular events have been reported with the COVID-19 vaccines, the causality is yet to be established because such CVS AEs are also usually associated with the general public even without intervention. Hence, people should be administered these vaccines, and sustained monitoring of these AEs should be done.Keywords: adverse events, COVID-19 vaccines, cardiovascular adverse events, Moderna, BNT162b2, 1222 AstraZeneca

Keywords

• adverse events
• covid-19 vaccines
• cardiovascular adverse events
• moderna
• bnt162b2
• 1222 astra zeneca